auto_awesome
Want to know who else bid on this?
ProposalForge correlates this contract with the original RFP, the losing bidders, and the next recompete window.
Department
National Research Council CanadaAmount
$10.0M
Province
ABType
Contribution
Agreement Number
172-2022-2023-Q3-998413
Purpose
Providence Therapeutics intends to continue the clinical development of a made-in-Canada mRNA vaccine against COVID-19. The firm is expecting to initiate a Phase 3 clinical trial on PTX-COVID19-B in mid-2023 and pursue market or emergency approvals to commercialize in late 2023 or early 2024. The objective of this project is to facilitate the company's R&D efforts and vaccine development program to begin a Phase 3 clinical trial in 2023.
Providence Therapeutics Holdings Inc. × National Research Council Canada
8 grants totalling $48.7M
Industrial Research Assistance Program – Contributions to Firms
26,784 grants totalling $5.1B
Related Grants
| Recipient | Amount | Program |
|---|---|---|
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| Entos Pharmaceuticals Inc. | $10.0M | Industrial Research Assistance Program –... |
| ILLUMIN INC. | $10.0M | Industrial Research Assistance Program –... |